1. ALLA AKTIER
  2. NYHETER
  3. VÄSTRA HAMNEN CORP. FINANCE

Västra Hamnen Corp. Finance

Nyheter Västra Hamnen Corp. Finance Nyheter alla bolag
Hej Visste du att du med vår premiumtjänst får fullständig historik i alla grafer, pressmeddelanden och andra notiser för dina favoritbolag direkt som DM i Discord samt en del andra godsaker? Du slipper dessutom störande annonser på sajten. Testa gratis i 14 dagar!

Xintela: Promising data for XSTEM in OA

  • Q&A with CEO Evy Lundgren-Åkerlund
  • Strong support for advancing XSTEM in OA
  • We reiterate our fair value of SEK 1.43 per share

Xintela recently announced promising interim data from its phase I/IIa study with XSTEM in knee osteoarthritis (OA). Data from 24 patients in all three dose levels have been analysed, 18 months after treatment. No serious safety or tolerability issues were recorded in the study and the company also received promising early efficacy data. Västra Hamnen contacted CEO Evy Lundgren-Åkerlund for a comment.

Read the full report here.

About Market Focus

The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.

This is a press release from Västra Hamnen Corporate Finance AB. 
Web: vhcorp.se
Twitter: @vhcorp_se (https://x.com/vhcorp_se)

Datum 2025-03-28, kl 08:33
Källa MFN